medigraphic.com

2010, Número 1

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2010; 48 (1)


El factor de transcripción nuclear kappa en las enfermedades humanas

Escárcega RO

Idioma: Español
Referencias bibliográficas: 32
Paginas: 55-60
Archivo PDF: 38.94 Kb.


RESUMEN

El factor de transcripción nuclear kappa B (NF-κB) fue descrito por primera vez en 1986. Actualmente ha sido ligado a un sinnúmero de enfermedades metabólicas, inflamatorias y diversos tipos de cáncer, y seguirá siendo de interés en diversos procesos de enfermedad inflamatorios, infecciosos y neoplásicos. El descubrimiento de este factor ha logrado ampliar nuestro conocimiento sobre la regulación de la inflamación y las enfermedades crónicas, así como de los fármacos para tratar dichas enfermedades.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46(5):705-716.

  2. Escárcega RO, Fuentes-Alexandro S, García- Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor kappa B and cancer. Clin Oncol (R Coll Radiol) 2007;19(2):154-161.

  3. Ghosh, S, May M, Kopp E. NF-kappa B and Rel proteins: evolutionarily conserved mediators of the immune response. Annu Rev Immunol 1998;16: 225-260.

  4. Yamamoto Y, Gaynor RB. Therapeutic potential of inihibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107(2):135-142.

  5. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, Opipari AW Jr. NF-kappa B activation mediates doxorubicininduced cell death in N-type neuroblastoma cells. J Biol Chem 2001;276(52):48921-48929.

  6. Brandt S, Kwok T, Harting R, Konlg W, Backert S. NF-kappa B activation and potentiation of proinflammatory responses by the Helicobacter Pylori CagA protein. Proc Natl Acad Sci USA 2005;102 (26):9300-9305.

  7. Abdel-Latif MM, O’Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004;239(4):491-500.

  8. Jimi E, Gosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev 2005; 208:80-87.

  9. Chen CC, Rosenbloom CL, Anderson DC, Maning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expresion by inhibitors of I kappa-B alpha phosphorilation. J Immunol 1995;155(7): 3538-3545.

  10. Tak PP, Firestein GS. NF-kappa B: A key role in inflammatory diseases. J Clin Invest 2001;107 (1):7-11.

  11. Han ZN, Boyle DL, Manning AM, Firestein GS. AP-I and NF-kappa B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28(4):197-208.

  12. Sakurai PP, Sakurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T. Activation of transcription factor NF-kappa B in experimental glomerulonephritis in rats. Biochem Biophys Acta 1996; 1316(2):132-138.

  13. Yang F, de Villiers WJ, Lee EY, McClain CJ, Varilek GW. Increased nuclear factor-kappa B activation in colitis of inteurleukin-2-deficient mice. J Lab Clin Med 1999;134(4):378-385

  14. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF. Activation and localization of transcription factor, nuclear factor-kappa B in asthma. Am J Resp Crit Care Med 1998;158(5 Pt 1):1585-1592

  15. Creus KK, De Paepe B, Werbrouck BF, Vervaet V, Weis J, De Bleecker JL. Distribution of the NFkappaB complex in the inflammatory exudates characterizing the idiopathic inflammatory myopathies. Ann N Y Acad Sci 2009;1173:370-377.

  16. DeLuca C, Petropolous L, Zmeureanu D, Hiscott J. Nuclear I kappa beta maintains persistent NFkappa B activation in HIV-1 infected myeloid cells. J Biol Chem 1999;274(19):13010-13016.

  17. Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF- kappa B pathway. J Clin Invest 2001;107(2):143-151.

  18. Paine E, Scheinman R, Baldwin A, Raab-Traub N. Expression of LMP1 in epithelial cells leads to activation of a select subset of NF-kappa B/Rel family proteins. J Virol 1995;69(7):4572-4576.

  19. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS, Liaw YF. Constitutive activation of nuclear factor kappa B in hepatocellular carcinoma. Cancer 2000;89(11):2274-2281.

  20. Li N, Karin M. Is NF-kappa B the sensor of oxidative stress? FASEB J 1999;13(10):1137-1143.

  21. Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A, et al. Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 1997; 17(10):1901-1909.

  22. Mazière C, Mazière JC. Activation of transcription factors and gene expression by oxidized lowdensity lipoprotein. Free Radic Biol Med 2009; 46(2):127-137.

  23. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor alpha: a direct role in obesity-linked insulin resistance. Science 1993;259(5091):87-91.

  24. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115(5):1111-1119.

  25. Escárcega RO, García-Carrasco M, Fuentes- Alexandro S, Jara LJ, Rojas-Rodríguez J, Escobar- Linares LE, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006;6(1):48-53.

  26. Ghosh S, May M, Kopp E. NF-kappa B and Rel proteins: evolutionarily conserved mediators of the immune response. Annu Rev Immunol 1998;16: 225-260.

  27. Luo JL, Kamata H, Karin M. IKK/NF-kappa B signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005;115(10): 2625-2632.

  28. Monks NR, Biswas DK, Pardee AB. Blocking antiapoptosis as a strategy for cancer chemotherapy. NF-kappa B as a target. J Cell Biochem 2004;92 (4):646-650.

  29. Orlowski RZ, Baldwin AS Jr. NF-kappa B as a therapeutic target in cancer. Trends Mol Med 2002;8(8): 385-389.

  30. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107(2):135-142.

  31. Wahl C, Liptay S, Adler G, Schmid RM. Sulfa-salazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1997;101(5):1163-1174.

  32. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270(5234): 286-290.




2020     |     www.medigraphic.com